drugset / Trial / NCT02458183

Vaccine -diphthEria -tetaNus -Acellular pertUssis-inactivated polioviruS

NCT02458183

Phase 3 Completed 476 enrolled Boryung Pharmaceutical Co., Ltd
RandomizedParallel-groupOpen-labelPrevention

Summary

The objective of this study is to assess the immunogenicity and safety of the DTaP-IPV combination vaccine compared with those of separate DTaP and IPV vaccines administered to healthy infants at 2, 4, and 6 months of age.

Timeline

Start
2015-02-02
Primary completion
2017-12-19
Completion
2018-05-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator DTaP vaccine Vaccine 0.5 ml Intramuscular
Subject DTaP-IPV combination vaccine Vaccine 0.5 ml Intramuscular
Comparator IPV vaccine Vaccine 0.5 ml Intramuscular